Markers for the Progression of IgA Nephropathy

Overview

Journal J Nephrol

Publisher Springer

Specialty Nephrology

Date 2016 May 5

PMID 27142988

Citations 39

Authors

Dita Maixnerova

Colin Reily

Qi Bian

Michaela Neprasova

Jan Novak

Vladimir Tesar

Affiliations

Soon will be listed here.

Abstract

We have summarized the latest findings on markers for progression of immunoglobulin A (IgA) nephropathy (IgAN), the most common primary glomerulonephritis with a high prevalence among end-stage renal disease (ESRD) patients. The clinical predictors of renal outcome in IgAN nephropathy, such as proteinuria, hypertension, and decreased estimated glomerular filtration rate (eGFR) at the time of the diagnosis, are well known. The Oxford classification of IgAN identified four types of histological lesions (known as the MEST score) associated with the development of ESRD and/or a 50 % reduction in eGFR. In addition, the role of genetic risk factors associated with IgAN is being elucidated by genome-wide association studies, with multiple risk alleles described. Recently, biomarkers in serum (galactose-deficient IgA1, IgA/IgG autoantibodies against galactose-deficient IgA1, and soluble CD 89-IgA complexes) and urine (soluble transferrin receptor, interleukin-6/epidermal growth factor ratio, fractalkine, laminin G-like 3 peptide, κ light chains, and mannan-binding lectin) have been identified. Some of these biomarkers may represent candidates for the development of noninvasive diagnostic tests, that would be useful for detection of subclinical disease activity, monitoring disease progression, assessment of treatment, and at the same time circumventing the complications associated with renal biopsies. These advances, along with future disease-specific therapy, will be helpful in improving the treatment effectiveness, prognosis, and the quality of life in connection with IgAN.

Citing Articles

The ratio of high aspartate aminotransferase to alanine aminotransferase: an independent risk factor associated with poor prognosis in IgA nephropathy.

Wei H, Liao B, Zhou Q, Zhou X, Zhong Y, Hao Y Clin Exp Nephrol. 2024; 28(11):1111-1120.

PMID: 38767689 DOI: 10.1007/s10157-024-02513-7.

Clinical significance of urinary inflammatory biomarkers in patients with IgA nephropathy.

Yoon S, Kim J, Jung S, Kim Y, Moon J, Lee S BMC Nephrol. 2024; 25(1):142.

PMID: 38649936 PMC: 11036669. DOI: 10.1186/s12882-024-03574-2.

The Effects of Extracts on IgA Nephropathy: A Systematic Review and Meta-Analysis.

Adam G, Adam A, Robu S, Harabor V, Harabor A, Nechita A Pharmaceuticals (Basel). 2023; 16(7).

PMID: 37513901 PMC: 10385934. DOI: 10.3390/ph16070988.

Urinary N-Acetyl-Beta-D-Glucosaminidase levels predict immunoglobulin a nephropathy remission status.

Liu X, Gong S, Ning Y, Li Y, Zhou H, He L BMC Nephrol. 2023; 24(1):208.

PMID: 37452282 PMC: 10347709. DOI: 10.1186/s12882-023-03262-7.

Global trends and hotspots in IgA nephropathy: a bibliometric analysis and knowledge map visualization from 2012 to 2023.

Wang J, Wang X, Cai X, Pan D Int Urol Nephrol. 2023; 55(12):3197-3207.

PMID: 37074616 PMC: 10113965. DOI: 10.1007/s11255-023-03598-x.

References

Barbour S, Reich H . Risk stratification of patients with IgA nephropathy. Am J Kidney Dis. 2012; 59(6):865-73. DOI: 10.1053/j.ajkd.2012.02.326. View

Bellur S, Troyanov S, Cook H, Roberts I . Immunostaining findings in IgA nephropathy: correlation with histology and clinical outcome in the Oxford classification patient cohort. Nephrol Dial Transplant. 2011; 26(8):2533-6. DOI: 10.1093/ndt/gfq812. View

Barbour S, Espino-Hernandez G, Reich H, Coppo R, Roberts I, Feehally J . The MEST score provides earlier risk prediction in lgA nephropathy. Kidney Int. 2016; 89(1):167-75. DOI: 10.1038/ki.2015.322. View

Szeto C, Li P . MicroRNAs in IgA nephropathy. Nat Rev Nephrol. 2014; 10(5):249-56. DOI: 10.1038/nrneph.2014.50. View

Torres D, Rossini M, Manno C, Mattace-Raso F, DAltri C, Ranieri E . The ratio of epidermal growth factor to monocyte chemotactic peptide-1 in the urine predicts renal prognosis in IgA nephropathy. Kidney Int. 2007; 73(3):327-33. DOI: 10.1038/sj.ki.5002621. View

Roberts I, Cook H, Troyanov S, Alpers C, Amore A, Barratt J . The Oxford classification of IgA nephropathy: pathology definitions, correlations, and reproducibility. Kidney Int. 2009; 76(5):546-56. DOI: 10.1038/ki.2009.168. View

Peters H, van den Brand J, Wetzels J . Urinary excretion of low-molecular-weight proteins as prognostic markers in IgA nephropathy. Neth J Med. 2009; 67(2):54-61. View

Reich H, Troyanov S, Scholey J, Cattran D . Remission of proteinuria improves prognosis in IgA nephropathy. J Am Soc Nephrol. 2007; 18(12):3177-83. DOI: 10.1681/ASN.2007050526. View

Kaartinen K, Syrjanen J, Porsti I, Hurme M, Harmoinen A, Pasternack A . Inflammatory markers and the progression of IgA glomerulonephritis. Nephrol Dial Transplant. 2007; 23(4):1285-90. DOI: 10.1093/ndt/gfm782. View

10.

Nakata J, Suzuki Y, Suzuki H, Sato D, Kano T, Yanagawa H . Changes in nephritogenic serum galactose-deficient IgA1 in IgA nephropathy following tonsillectomy and steroid therapy. PLoS One. 2014; 9(2):e89707. PMC: 3931817. DOI: 10.1371/journal.pone.0089707. View

11.

Candiano G, Musante L, Bruschi M, Petretto A, Santucci L, Del Boccio P . Repetitive fragmentation products of albumin and alpha1-antitrypsin in glomerular diseases associated with nephrotic syndrome. J Am Soc Nephrol. 2006; 17(11):3139-48. DOI: 10.1681/ASN.2006050486. View

12.

Hastings M, Moldoveanu Z, Julian B, Novak J, Sanders J, McGlothan K . Galactose-deficient IgA1 in African Americans with IgA nephropathy: serum levels and heritability. Clin J Am Soc Nephrol. 2010; 5(11):2069-74. PMC: 3001782. DOI: 10.2215/CJN.03270410. View

13.

Suzuki H, Ohsawa I, Kodama F, Nakayama K, Ohtani A, Onda K . Fluctuation of serum C3 levels reflects disease activity and metabolic background in patients with IgA nephropathy. J Nephrol. 2013; 26(4):708-15. DOI: 10.5301/jn.5000278. View

14.

Kiryluk K, Li Y, Sanna-Cherchi S, Rohanizadegan M, Suzuki H, Eitner F . Geographic differences in genetic susceptibility to IgA nephropathy: GWAS replication study and geospatial risk analysis. PLoS Genet. 2012; 8(6):e1002765. PMC: 3380840. DOI: 10.1371/journal.pgen.1002765. View

15.

Ranieri E, Gesualdo L, Petrarulo F, Schena F . Urinary IL-6/EGF ratio: a useful prognostic marker for the progression of renal damage in IgA nephropathy. Kidney Int. 1996; 50(6):1990-2001. DOI: 10.1038/ki.1996.521. View

16.

Cattran D, Coppo R, Cook H, Feehally J, Roberts I, Troyanov S . The Oxford classification of IgA nephropathy: rationale, clinicopathological correlations, and classification. Kidney Int. 2009; 76(5):534-45. DOI: 10.1038/ki.2009.243. View

17.

Yasutake J, Suzuki Y, Suzuki H, Hiura N, Yanagawa H, Makita Y . Novel lectin-independent approach to detect galactose-deficient IgA1 in IgA nephropathy. Nephrol Dial Transplant. 2015; 30(8):1315-21. PMC: 4513896. DOI: 10.1093/ndt/gfv221. View

18.

Serino G, Sallustio F, Cox S, Pesce F, Schena F . Abnormal miR-148b expression promotes aberrant glycosylation of IgA1 in IgA nephropathy. J Am Soc Nephrol. 2012; 23(5):814-24. PMC: 3338289. DOI: 10.1681/ASN.2011060567. View

19.

Wang N, Bu R, Duan Z, Zhang X, Chen P, Li Z . Profiling and initial validation of urinary microRNAs as biomarkers in IgA nephropathy. PeerJ. 2015; 3:e990. PMC: 4458130. DOI: 10.7717/peerj.990. View

20.

Wyatt R, Julian B . IgA nephropathy. N Engl J Med. 2013; 368(25):2402-14. DOI: 10.1056/NEJMra1206793. View